New Delhi: Like every other crisis, the COVID-19 pandemic, which triggered an unprecedented countrywide lockdown less than a year

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the "first interim analysis" of

India’s status fell from “free” to “partly free” in the